The Division of Hematology/Oncology at Indiana University School of Medicine is a part of the IU Melvin and Bren Simon Comprehensive Cancer Center, a National Cancer Institute (NCI)-designated comprehensive cancer center, and the only center with such distinction in Indiana. The school’s Division of Hematology-Oncology is comprised of a diverse faculty with expertise in every major hematologic and oncology disease. The division has a multi-disciplinary clinic in prostate cancer, lung cancer, breast cancer, gastrointestinal tumors, head and neck cancer, melanoma, testicular, bone marrow transplant, and precision genomics, among others.
Indiana University's Hematology/Oncology Fellowship is one of the oldest programs in the United States, being established by Dr. Lawrence Einhorn in 1975. Graduates from IU have a long track of success including two ASCO presidents, one ASH president, four ASCO presidential candidates, and ten faculty that have served as chairs on various ECOG committees. Indiana University has published multiple landmark trials in the areas of lung, colon, bladder, breast, pancreas, ovarian, germ cell tumors, anti-emetics, quality of life, and survivorship. Indiana University is credited with making the previously fatal disseminated testicular cancer the now highly curable disease we see today. Research from IU has also led to FDA approval of six drugs.